Prescribers and pharmacists across the North Coast will have access to SafeScript NSW from early March 2022, as part of a phased statewide rollout.
SafeScript NSW provides prescribers and pharmacists with real-time information about a patient’s prescribing and dispensing history for certain high-risk medicines, known as monitored medicines. This information helps to improve clinical decision making and keep patients safe.
Prescribers and pharmacists in the Hunter New England and Central Coast PHN were the first to have access to SafeScript NSW from October 2021. More than 25% of eligible health practitioners have already registered for the system. Many are finding it to be an easy-to-use, helpful clinical tool.
‘It is integrated really well and is easy to use. I have a lot more insight and information about what is going on with patients now.’ – General practitioner
‘It’s an essential tool for pharmacists to dispense medications safety.’ – Pharmacist
Who is eligible to access SafeScript NSW?
All prescribers (medical practitioners and nurse practitioners) and pharmacists who are registered with the Australian Health Practitioner Regulation Agency will be able to access the system when it becomes available.
What to expect when SafeScript NSW becomes available
Eligible prescribers and pharmacists will receive an invitation to register for SafeScript NSW by email to the address registered with AHPRA. Registration is a simple 10-minute process. Step-by-step instructions will be provided.
Support and resources
Prescribers and pharmacists are being supported during the rollout of SafeScript NSW and will have ongoing access to resources.
To prepare for the arrival of SafeScript NSW:
- complete a series of CPD eLearning modules, which explain how and when to use the system, information about monitored medicines and clinical practice, and how to support patients who may be at risk of harm
- learn about the support available, including a dedicated 24/7 clinical advice line.
For more information, visit the website or send enquiries to: [email protected]